November – December 2023

Bowel

Mirikizumab as induction and maintenance therapy for ulcerative colitis:

The interleukin-23 antibody mirikizumab was more effective than placebo in inducing and maintaining clinical remission in patients with moderately to severely active ulcerative colitis in a phase III trial program. However, opportunistic infection or cancer occurred in a small number patients treated with mirikizumab.

Liver

Chronic hepatitis D: 45% combined virological and biochemical response on bulevirtide therapy for 48 weeks.

The recently published 48-week data from the ongoing MYR301 trial demonstrate that bulevirtide (2 mg/day subcutaneously) leads to a combined virological and biochemical response in 45% of patients with chronic hepatitis D (HDV RNA undetectable or decline of at least 2 log10 IU/ml and normalization of alanine aminotransferase). However, HDV RNA became undetectable in only 12% of patients.

Oesophagus Stomach Duodenum

Pancreas

Archives

Categories

Live Sessions

Para ingresar a las sesiones en vivo es necesario registrarse:

Si ya esta registrado ingrese al sitio con su nombre de usuario y su password:

x

Estimado Médico
Suscríbase
Para tener acceso a artículos exclusivos de la revista gastroenterología


En su suscripción recibirá mensualmente nuestro boletín con noticias, eventos y sesiones en vivo.

Si ya esta registrado ingrese aquí

Estimado Médico
Suscríbase
Para tener acceso a artículos exclusivos de la revista gastroenterología


En su suscripción recibirá mensualmente nuestro boletín con noticias, eventos y sesiones en vivo.

Si ya esta registrado ingrese aquí